MEA Orthobiologics Market

MEA Orthobiologics Market Size (2023 to 2028)

The size of the Orthobiologics Market in the Middle East & Africa was worth USD 416.12 million in 2023 and estimated to be growing at a CAGR of 4.03%, to reach USD 507.00 million by 2028. 

Regenerative cellular therapies are another name for orthobiologics. Orthobiologics products contain or produce growth factors to aid tissue repair, reduce pain, and help restore normal function. There are many distinct forms of orthobiologics on the market, each with its own mode of action. Autologous stem cells are produced from the patient's body and divide under the correct conditions to form progenitor cells. Orthobiologics are mostly used to aid in the speedier healing of injuries.

The rise in the geriatric population, which is more susceptible to diseases such as osteoarthritis and others, is fueling the expansion of the orthobiologics market in the MEA region. Other factors projected to drive the market growth include increased awareness of orthobiologics and increased demand for improved therapy. In addition, the rise in obesity and the number of sports and road accidents are all contributing to the expansion of the orthobiologics industry in the MEA.

The further expansion in the orthobiologics sector is mostly due to increased demand and rapid adoption of newly developed products such as Medtronic's Infuse, a bone morphogenetic protein, and others. In addition, the market growth is also likely to be accelerated as the prevalence of the disease grows and the introduction of innovative products.

The MEA orthobiologics market is forecasted to be hampered by difficult syncretization procedures, industrial rules, and high production costs. In addition, high costs and poor reimbursements for orthobiologics goods and procedures are other important issues limiting the market's growth. One of the other major obstacles to the MEA orthobiologics market's growth is the high cost of orthobiologics treatments and products.

This research report on the MEA orthobiologics market has been segmented & sub-segmented into the following categories:

By Product: 

• Viscosupplementation
• Demineralized Bone Matrices
• Synthetic Orthobiologics
• Bone Morphogenic Protein
• Allografts
• Plasma-Rich Protein
• Bone Marrow Aspirate Concentrate

By Application: 

• Osteoarthritis and Degenerative Arthritis
• Spinal Fusion
• Fracture Recovery
• Soft Tissue Injuries
• Maxillofacial & Dental Applications

By End Users: 

• Hospitals
• Orthopedic Clinics
• Ambulatory Care Centres
• Research and Academic Institutes
• Dental Clinics & Facilities

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Geographically, due to increased demand for treatment of sports injuries and an increase in government activities to raise awareness of orthobiologics, the Middle East and Africa are likely to have significant market potential in the foreseeable future. The novel treatments are projected to effectively lower surgical problems, propelling the orthobiologics market forward during the forecast period. The increased incidence of orthopedics disease and musculoskeletal disorders are important driving factors in the MEA orthobiologics market. As the disease's prevalence rises, and so will the development of innovative solutions in this region, market demand is expected to accelerate.

Furthermore, growing technological breakthroughs in biomaterials utilized in orthobiologics are projected to boost market demand during the forecast period, according to MEA. The introduction of recombinant biologic medicines, changes in graft designs, cultured tissue scaffolds, and stem cell therapy are all examples of these. These advancements come with advantages, including shorter operating times, improved biocompatibility, and smaller incisions.

During the forecast period, the market players are expected to benefit from the strong development potential in this region and an increase in demand for sophisticated therapy. Hospitals account for a sizable portion of the end-user market in this region. The key driver giving the most important shares to this segment is the increasing acceptance of ortho biological products in a wide range of spinal and reconstructive procedures conducted in hospitals. This market is expected to develop due to specialized patient care and the simple availability of a large range of orthobiologics in hospitals.

KEY MARKET PLAYERS:

Medtronic, DePuy Synthes, Zimmer Biomet, Bioventus, Stryker, Harvest Technologies, Globus, Orthofix International, RTI Surgical, K2M Group, and Kuros Biosciences are some of the key players in the MEA orthobiologics market.